You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Osmotica Pharm Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for OSMOTICA PHARM, and what generic and branded alternatives to OSMOTICA PHARM drugs are available?

OSMOTICA PHARM has ten approved drugs.

Summary for Osmotica Pharm

US Patents:	0
Tradenames:	10
Ingredients:	9
NDAs:	10
Patent Litigation for Osmotica Pharm:	See patent lawsuits for Osmotica Pharm

Drugs and US Patents for Osmotica Pharm

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Osmotica Pharm Us	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205327-004	Jul 28, 2017	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Osmotica Pharm Us	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205327-003	Jul 28, 2017	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Osmotica Pharm Us	CARBAMAZEPINE	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	215664-001	Oct 22, 2024	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Osmotica Pharm Us	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	078503-002	Feb 4, 2009	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Osmotica Pharm Us	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205327-002	Jul 28, 2017	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Osmotica Pharm

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-003	May 20, 2008	6,403,120	⤷ Subscribe
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-001	May 20, 2008	6,403,120	⤷ Subscribe
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-004	May 20, 2008	6,403,120	⤷ Subscribe
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-003	May 20, 2008	6,419,958	⤷ Subscribe
Osmotica Pharm Us	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022104-002	May 20, 2008	6,419,958	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.